PulseSight Therapeutics launches to advance non-viral gene therapies for severe retinal diseases
February 28th 2024According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.
Study: Treatment developed to dramatically slow progression of blindness-causing retinal diseases
February 24th 2024Researchers have found that the interactive release of anti-inflammatory drugs depend on the level of retinal degeneration. A customized treatment approach is expected to be developed to reduce patients’ inconvenience of having multiple shots.